Sector News

Bayer plans to scale back women’s health R&D

March 31, 2023
Life sciences

Ahead of a change in leadership at the top after the upcoming annual general meeting, in interviews with news agencies Bayer is dropping hints in dribbles about future plans for its healthcare business.

In the latest dribble, the German healthcare and agrochemicals giant told Reuters that in future its pharma pipeline will focus on cardiovascular disease, neurology, rare diseases and immunology, while de-emphasizing women’s health, a field it first focused on with the acquisition of the former women’s health specialist Schering in 2006.

Stefan Oelrich, head of the Pharmaceuticals division, said that while the Jasmin-branded oral contraceptives and the Mirena intrauterine device inherited from Schering will take a back seat in the company’s future corporate drugs strategy, Bayer is still committed to clinical-stage products, including elinzanetant to treat vasomotor symptoms during menopause. Here it projects peak sales of more than €1 billion.

The pharma chief pointed to recent acquisitions that will position Bayer to become a major player in cell and gene therapy.

In the nearly 20 years it has owned Schering franchise – which also had a significant position in oncology – Oelrich acknowledged that Bayer’s own research into therapeutics for women has not met expectations.

At the time, Schering was Bayer’s largest-ever acquisition. The then-integrated pharmaceuticals and chemicals group, at the urging of the Berlin-based pharma’s management, rode up from Leverkusen to the nation’s capital as a “white knight” to snatch the company from the jaws of Germany’s Merck, which was attempting a hostile takeover with a view to widening its own women’s health franchise.

As yet, Bayer has given no indication that it may seek to unload the franchise.

By: Dede Williams, Freelance Journalist

Source: chemanager-online.com

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach